These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 8164379)
21. [Glucocorticoids in ophthalmology- therapeutic value and strategies of rational utilization]. Cârstocea B; Selaru D; Serban MM Oftalmologia; 2001; 52(2):47-53. PubMed ID: 11771102 [TBL] [Abstract][Full Text] [Related]
22. [Cortisonoids in the therapy of rheumatic diseases]. Reinicke C Z Gesamte Inn Med; 1977 Jul; 32(14):338-43. PubMed ID: 335682 [TBL] [Abstract][Full Text] [Related]
23. Complications of intravitreal steroid injections. Reichle ML Optometry; 2005 Aug; 76(8):450-60. PubMed ID: 16150412 [TBL] [Abstract][Full Text] [Related]
24. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Jonas JB Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641 [TBL] [Abstract][Full Text] [Related]
25. [The clinical analysis of corticosteroid ocular hypertension and corticosteroid glaucoma after photorefractive keratectomy]. Li C; Zhang J; Huang C Zhonghua Yan Ke Za Zhi; 1999 May; 35(3):179-82. PubMed ID: 11835800 [TBL] [Abstract][Full Text] [Related]
26. [Is subconjunctival steroid administration in addition to local therapy after cataract operations necessary? A laser tyndallometric study]. Schmitt K; Hessemer V Ophthalmologe; 1995 Jun; 92(3):303-6. PubMed ID: 7655203 [TBL] [Abstract][Full Text] [Related]
27. [POSTERIOR SUBCAPSULAR CATARACT OBSERVED IN CASES ADMINISTERED MASSIVE DOSE OF CORTICOSTEROIDS FOR A LONG PERIOD]. TODA S; TAHARA H Nihon Ganka Kiyo; 1964 Feb; 15():61-5. PubMed ID: 14136641 [No Abstract] [Full Text] [Related]
28. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T; Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification. Wadood AC; Armbrecht AM; Aspinall PA; Dhillon B J Cataract Refract Surg; 2004 Apr; 30(4):761-8. PubMed ID: 15093636 [TBL] [Abstract][Full Text] [Related]
32. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645 [TBL] [Abstract][Full Text] [Related]
33. [New aspects on systemic adverse effects of ocular drugs]. Uusitalo H; Salminen L Duodecim; 1998; 114(3):287-92. PubMed ID: 10895504 [No Abstract] [Full Text] [Related]
34. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Myles ME; Neumann DM; Hill JM Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884 [TBL] [Abstract][Full Text] [Related]
35. Outcome of raised intraocular pressure in uveitic eyes with and without a corticosteroid-induced hypertensive response. Sallam A; Sheth HG; Habot-Wilner Z; Lightman S Am J Ophthalmol; 2009 Aug; 148(2):207-213.e1. PubMed ID: 19403113 [TBL] [Abstract][Full Text] [Related]
36. [Diclof 0.1% eyedrops in pediatric ophthalmology]. Gerinec A; Kostolná B Cesk Slov Oftalmol; 2001 May; 57(3):200-3. PubMed ID: 11433596 [TBL] [Abstract][Full Text] [Related]